1887

Abstract

Purpose. The analytical performance of the cobas 6800 HIV-1, HBV and HCV assays was verified and evaluated to the COBAS Ampliprep/COBAS TaqMan assays.

Methodology. The precision, limit of detection (LoD), limit of quantification (LoQ) and linearity were verified using pooled residual clinical samples. The analytical specificity was verified with negative plasma. HIV-1 analytical reactivity was verified with WHO reference preparations. Accuracy was verified using EQA plasma panels. Evaluation of the equipment was performed using prospectively collected clinical whole blood samples.

Results. Excellent precision was demonstrated using both testing protocols (coefficient of variation ≤15 %). The LoDs using the 500 and 200 µl protocols were 20 and 50 cp ml for HIV-1, 10 and 20 IU ml for HBV and 15 and 40 IU ml for HCV, respectively. The LoQs were 40 and 100 cp ml for HIV-1, 20 and 25 IU ml for HBV and 30 and 80 IU ml for HCV, respectively. Assays demonstrated good linearity (R ≥0.96). The analytical specificity of the assays was 100 %. There was excellent agreement between the cobas 6800 and CAP/CTM assays (kappa>0.94). The sensitivity, specificity, positive predictive value and negative predictive value for each of the assays were ≥99 %. The cobas HIV-1 and HCV mean quantifications were 0.03 log10 cp ml and 0.17 log10 IU ml higher than the CAP/CTM. The cobas HBV mean quantification was 0.17 log10 IU ml lower than the CAP/CTM. Subtype/genotype specific differences were not observed.

Conclusion. Cobas 6800 equipment and assays demonstrated excellent performance and correlated well with CAP/CTM assay results.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000838
2018-10-16
2019-12-06
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/12/1711.html?itemId=/content/journal/jmm/10.1099/jmm.0.000838&mimeType=html&fmt=ahah

References

  1. UK Standards for Microbiology Investigations Anti-HIV Screening. Version 11, Issue 3.2. 2014;1–11www.gov.uk/government/collections/standards-for-microbiology-investigations-smi [accessed on 27 April 2016]
  2. UK Standards for Microbiology Investigations Investigation of Hepatitis. Issue 1.2. 2014;1–44www.gov.uk/government/collections/standards-for-microbiology-investigations-smi [accessed on 27 April 2016]
  3. Churchill D, Waters L, Ahmed N, Angus B, Boffito M et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med 2016;17:s2–s104 [CrossRef][PubMed]
    [Google Scholar]
  4. Asboe D, Aitken C, Boffito M, Booth C, Cane P et al. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med 2012;13:1–44 [CrossRef][PubMed]
    [Google Scholar]
  5. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (updated 14.07.2016). www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [accessed on 9 September 2016]
  6. European Association For The Study Of The Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–185 [CrossRef][PubMed]
    [Google Scholar]
  7. European Association For The Study Of The Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392–420 [CrossRef][PubMed]
    [Google Scholar]
  8. The National Institute for Health and Care Excellence NICE clinical guideline [CG165]: Hepatitis B (chronic): diagnosis and management (updated Oct 2017). www.nice.org.uk/guidance/cg165/resources/hepatitis-b-chronic-diagnosis-and-management-pdf-35109693447109 [accessed on 25 June 2018]
  9. The National Institute for Health and Care Excellence NICE technology appraisal guidance: Elbasvir-grazoprevir for treating chronic hepatitis C (26 th Oct 2016). www.nice.org.uk/guidance/ta413/resources/elbasvirgrazoprevir-for-treating-chronic-hepatitis-c-pdf-82604601546181 [accessed on 25 June 2018]
  10. Cobb B, Simon CO, Stramer SL, Body B, Mitchell PS et al. The cobas®6800/8800 System: a new era of automation in molecular diagnostics. Expert Rev Mol Diagn 2017;17:167–180 [CrossRef][PubMed]
    [Google Scholar]
  11. The British Standards Institution Medical Laboratories &Ndash; Requirements for Quality and Competence (ISO 15189:2012) United Kingdom: BSI Standards Publication; 2012; pp.1–62
    [Google Scholar]
  12. Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F et al. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. J Clin Virol 2017;96:49–53 [CrossRef][PubMed]
    [Google Scholar]
  13. Maasoumy B, Bremer B, Lehmann P, Marins EG, Michel-Treil V et al. Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. Therap Adv Gastroenterol 2017;10:609–618 [CrossRef][PubMed]
    [Google Scholar]
  14. Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C et al. Multicenter comparison study of both analytical and clinical performance across four roche hepatitis C Virus RNA assays utilizing different platforms. J Clin Microbiol 2017;55:1131–1139 [CrossRef][PubMed]
    [Google Scholar]
  15. Yao JD, Young S, Heilek GM, Marino E, Paxinos EE et al. Diagnosis and monitoring of HCV infection using the cobas® HCV test for use on the cobas® 6800/8800 systems. J Clin Virol 2018;102:63–69 [CrossRef][PubMed]
    [Google Scholar]
  16. Pas S, Rossen JW, Schoener D, Thamke D, Pettersson A et al. Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2010;48:1195–1200 [CrossRef][PubMed]
    [Google Scholar]
  17. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007;46:22–31 [CrossRef][PubMed]
    [Google Scholar]
  18. Elkady A, Tanaka Y, Kurbanov F, Sugauchi F, Sugiyama M et al. Performance of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. J Med Virol 2010;82:1878–1888 [CrossRef][PubMed]
    [Google Scholar]
  19. de Bel A, Marissens D, Debaisieux L, Liesnard C, van den Wijngaert S et al. Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol 2010;48:1337–1342 [CrossRef][PubMed]
    [Google Scholar]
  20. Vermehren J, Colucci G, Gohl P, Hamdi N, Abdelaziz AI et al. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol 2011;49:3309–3315 [CrossRef][PubMed]
    [Google Scholar]
  21. Roche Diagnostics GmbH MFSN0115_FSN_RMD_2015_008_ Potential for Sample Under-aspiration with Low Sample Input Volume Assays - cobas ® 6800/8800 systems (Urgent Field Safety Notice) United Kingdom: Roche Molecular Diagnostics; 2015; pp.1–3
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000838
Loading
/content/journal/jmm/10.1099/jmm.0.000838
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error